Type 1 diabetes mellitus develops as a result of complete failure of pancreatic beta cells, resulting in no insulin secretion and very low levels of secretion in the body. Currently, the main clinical treatment for type 1 diabetes is multiple daily insulin subcutaneous injections or insulin pump therapy. Pancreatic β-cell transplantation for type 1 diabetes mellitus is a treatment that has been expected to completely eradicate type 1 diabetes mellitus with great hope. However, it has not yet been used in the clinic because some key technologies have not yet been solved, resulting in insufficient durability of its efficacy. In recent years, due to the advances in insulin pump technology and blood glucose monitoring, the combination of insulin pump and dynamic glucose monitoring is a relatively new approach to treating type 1 diabetes, which can reduce the pain of multiple injections and repeated blood glucose measurements, as well as the ability to see the fluctuations in blood glucose at any time, anywhere, and replenish the injection of insulin at any time. However, this is only an upgrade in treatment technology and does not yet cure type 1 diabetes at its root.